The Latest Breaking News from DXCM

Despite DexCom’s underperformance relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.

DexCom is poised to announce its third-quarter results later this month, with analysts predicting a double-digit decline in the company's earnings.

Despite DexCom’s underperformance compared to the S&P 500 Index over the past year, Wall Street analysts are highly bullish about the stock’s prospects.

Despite DexCom lagging behind the broader market over the past year, Wall Street analysts remain bullish on the stock’s prospects.

Dexcom stock is crashing Friday after the glucose monitoring company reported dismal Q2 revenue and slashed its full-year sales guidance. Here's what you need to know.

Amid a broader market rotation out of Big Tech stocks, investors can consider these three top-rated healthcare stocks with double-digit upside potential.

DexCom is gearing up to announce its second-quarter results this month, and analysts are anticipating a double-digit increase in the company’s bottom-line figure.

Despite DexCom’s underperformance compared to its industry, Wall Street analysts remain optimistic about the stock’s prospects.

The healthcare industry is poised for tremendous growth driven by the aging population and rising incidence of chronic diseases. Hence, quality healthcare stocks, Danaher (DHR), Amgen (AMGN), and DexCom (DXCM), benefiting from an aging population, might be worth looking into. Read more….

Someone with a lot of money to spend has taken a bullish stance on DexCom (NASDAQ:DXCM). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

DexCom (NASDAQ:DXCM) has outperformed the market over the past 15 years by 20.9% on an annualized basis producing an average annual return of 27.35%. Currently, DexCom has a market capitalization of $30.77 billion.